Short Interest in bioMerieux (OTCMKTS:BMXMF) Declines By 42.6%

bioMerieux (OTCMKTS:BMXMF) was the target of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totaling 75,449 shares, a decrease of 42.6% from the April 15th total of 131,417 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 260 shares, the days-to-cover ratio is currently 290.2 days.

bioMerieux Stock Performance

Shares of BMXMF opened at $84.00 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48. The company’s 50 day simple moving average is $102.04 and its 200 day simple moving average is $115.34. bioMerieux has a 1 year low of $77.38 and a 1 year high of $152.00.

Analyst Upgrades and Downgrades

BMXMF has been the topic of several research reports. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. BNP Paribas Exane lowered shares of bioMerieux to a “neutral” rating in a research report on Wednesday, January 28th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of bioMerieux from a “buy” rating to a “hold” rating in a research report on Friday, April 24th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, bioMerieux has a consensus rating of “Hold”.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.